Ignite Creation Date:
2024-05-06 @ 4:30 PM
Last Modification Date:
2024-10-26 @ 2:11 PM
Study NCT ID:
NCT05007236
Status:
COMPLETED
Last Update Posted:
2022-04-21
First Post:
2021-08-09
Brief Title:
Study to Evaluate the Efficacy and Safety of Oral RP7214 a DHODH Inhibitor in Patients With Symptomatic Mild COVID-19 Infection
Sponsor:
Rhizen Pharmaceuticals SA
Organization:
Rhizen Pharmaceuticals SA
Study Overview
Official Title:
A Randomized Double-blind Placebo-controlled Phase 2 Study to Evaluate the Efficacy and Safety of Oral RP7214 a DHODH Inhibitor in Patients With Symptomatic Mild SARS-CoV-2 Infection
Status:
COMPLETED
Status Verified Date:
2022-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a randomized double-blind placebo-controlled study of RP7214 in patients with symptomatic mild SARS-CoV-2 infection having at least one high-risk feature eg age 60 years hypertension diabetes mellitus chronic lung disease chronic kidney disease liver disease cerebrovascular disease obesity cancer for developing severe Covid-19 illness
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None